Lyra Therapeutics 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Maria Palasis

최고 경영자

US$1.8m

총 보상

CEO 급여 비율	32.7%
CEO 임기	9.8yrs
CEO 소유권	n/a
경영진 평균 재임 기간	2.3yrs
이사회 평균 재임 기간	4.1yrs

최근 관리 업데이트

Recent updates

Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

Jan 25

We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Sep 10

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 12

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 30

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

Dec 14

We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

Aug 28

We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

May 04

How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Mar 05

Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Jan 11

Lyra Therapeutics down 19% underwhelming data from lead program

Dec 07

Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis

Nov 24

CEO 보상 분석

Maria Palasis 의 보수는 Lyra Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$98m
Jun 30 2024	n/a	n/a	-US$101m
Mar 31 2024	n/a	n/a	-US$69m
Dec 31 2023	US$2m	US$583k	-US$63m
Sep 30 2023	n/a	n/a	-US$62m
Jun 30 2023	n/a	n/a	-US$61m
Mar 31 2023	n/a	n/a	-US$60m
Dec 31 2022	US$2m	US$583k	-US$55m
Sep 30 2022	n/a	n/a	-US$55m
Jun 30 2022	n/a	n/a	-US$51m
Mar 31 2022	n/a	n/a	-US$48m
Dec 31 2021	US$2m	US$552k	-US$44m
Sep 30 2021	n/a	n/a	-US$37m
Jun 30 2021	n/a	n/a	-US$32m
Mar 31 2021	n/a	n/a	-US$26m
Dec 31 2020	US$4m	US$471k	-US$22m
Sep 30 2020	n/a	n/a	-US$20m
Jun 30 2020	n/a	n/a	-US$18m
Mar 31 2020	n/a	n/a	-US$17m
Dec 31 2019	US$843k	US$388k	-US$17m

보상 대 시장: Maria 의 총 보상 ($USD 1.79M )은 US 시장( $USD 652.28K ).

보상과 수익: 회사가 수익성이 없는 동안 Maria 의 보상이 증가했습니다.

CEO

Maria Palasis (59 yo)

9.8yrs

테뉴어

US$1,785,375

보상

Dr. Maria Palasis, Ph D, serves as Director at PanTher Therapeutics, Inc. since June 2021. Dr. Palasis has been Chief Executive Officer, President and Director of Lyra Therapeutics, Inc. since January 2015...

리더십 팀

이름	위치	테뉴어	보상	소유권
Harlan Waksal	Executive Chairman	2.8yrs	US$625.06k	0.40% $ 46.6k
Maria Palasis	CEO, President & Director	9.8yrs	US$1.79m	데이터 없음
Carmichael Roberts	Co-Founder	no data	데이터 없음	데이터 없음
Jason Cavalier	CFO, Treasurer & Secretary	3.2yrs	US$1.07m	데이터 없음
Ray Knox	Vice President of Operations	no data	데이터 없음	데이터 없음
Ronan O'Brien	Chief Legal Officer	1.1yrs	데이터 없음	데이터 없음
Vineeta Belanger	Senior Vice President of Clinical Affairs	no data	데이터 없음	데이터 없음
Robert Richard	Senior Vice President of Technical Operations	1.8yrs	US$666.79k	데이터 없음
Robert Kern	Chief Clinical Advisor	3.8yrs	데이터 없음	데이터 없음
Gloria Cosgrove	Senior Vice President of Quality	1.8yrs	데이터 없음	데이터 없음
Allison Nance	Senior Vice President of Regulatory Affairs	1.8yrs	데이터 없음	데이터 없음
Elazer Edelman	VP of Finance & Risk	no data	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: LYRA 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Harlan Waksal	Executive Chairman	2.8yrs	US$625.06k	0.40% $ 46.6k
Maria Palasis	CEO, President & Director	9.8yrs	US$1.79m	데이터 없음
James Tobin	Lead Independent Director	2.7yrs	US$152.31k	0% $ 0
W. Smith	Independent Director	5yrs	US$123.81k	0% $ 0
George Whitesides	Member of Scientific Advisory Board	4.1yrs	US$333.93k	데이터 없음
C. Merrifield	Independent Director	5.2yrs	US$113.06k	0.017% $ 2.0k
Robert Langer	Member of Scientific Advisory Board	4.1yrs	US$19.36k	데이터 없음
Michael Dake	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
William Gray	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Mahmood Razavi	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Gary Ansel	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
I. Baumgartner	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음

4.1yrs

평균 재임 기간

73yo

평균 연령

경험이 풍부한 이사회: LYRA 의 이사회는 경험(평균 재직 기간 4.1 년)으로 간주됩니다.

Lyra Therapeutics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Lyra Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Executive Chairman recently bought US$74k worth of stock

Lyra Therapeutics, Inc Announces Appointment of Ronan O’Brien as Chief Legal Officer

High number of new directors

Lyra Therapeutics Announces Appointment of Richard Nieman, Md, as Chief Medical Officer, Effective July 11, 2022

High number of new directors

Recent updates

Lyra Therapeutics, Inc. Fully Enrolls Pivotal Phase 3 Enlighten 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Lyra Therapeutics, Inc. Announces Impairment of Property and Equipment for the Quarter Ended June 30, 2024

Lyra Therapeutics, Inc. Announces Impairment of Property and Equipment for the Quarter Ended June 30, 2024

Lyra Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Lyra Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Price target decreased by 8.3% to US$11.00

Lyra Therapeutics, Inc. Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

Price target decreased by 8.3% to US$11.00

Consensus revenue estimates increase by 14%, EPS downgraded

New major risk - Financial position

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Lyra Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

Executive Chairman recently bought US$74k worth of stock

Consensus revenue estimates increase by 17%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Lyra Therapeutics, Inc Announces Appointment of Ronan O’Brien as Chief Legal Officer

Price target increased by 15% to US$12.20

Lyra Therapeutics Announces Positive Topline Results from Beacon Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis in Patients with Prior Ethmoid Sinus Surgery

We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 24%

Consensus EPS estimates upgraded to US$1.66 loss

Lyra Therapeutics, Inc. announced that it expects to receive $44.11725 million in funding

Consensus revenue estimates increase by 92%, EPS downgraded

Now 23% undervalued after recent price drop

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

High number of new directors

Lyra Therapeutics Inc. Advances Phase 2 Beacon Clinical Trial of Lyr-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study

Lyra Therapeutics, Inc. Announces New LYR-210 data analyses from the Phase 2 LANTERN study

Lyra Therapeutics Announces First Patient Enrolled in Pivotal Enlighten II Clinical Trial of Lyr-210 in Chronic Rhinosinusitis Patients

Consensus revenue estimates fall by 21%

Consensus revenue estimates increase by 17%

Lyra Therapeutics Announces Appointment of Richard Nieman, Md, as Chief Medical Officer, Effective July 11, 2022

Lyra Therapeutics appoints Nieman as Chief Medical Officer

Lyra Therapeutics, Inc.(NasdaqGM:LYRA) dropped from Russell Microcap Value Index

Price target decreased to US$20.67

Lyra Therapeutics: Progress In The Clinic

Consensus forecasts updated

Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022

High number of new directors

Lyra Therapeutics, Inc. Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

A First Look At Lyra Therapeutics

Lyra Therapeutics, Inc. announced that it has received $100.494971 million in funding from a group of investors

Lyra Therapeutics, Inc. announced that it expects to receive $100.494971 million in funding

High number of new directors

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

Lyra Therapeutics, Inc. Appoints Jim Tobin to Board of Directors

High number of new directors

Lyra Therapeutics, Inc. Announces Enrollment of First Patient in Phase 3 ENLIGHTEN I Clinical Trial of LYR-210 in Adult Patients with Chronic Rhinosinusitis

Lyra Therapeutics Appoints Harlan W. Waksal as Executive Chairman

Lyra Therapeutics, Inc. Announces Initiation of LYR-210 Pivotal Phase 3 Enlighten Program in Surgically Naïve Chronic Rhinosinusitis Patients

Price target decreased to US$24.00

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

Lyra Therapeutics, Inc. Announces Publication of Positive Lantern Results in the International Forum of Allergy & Rhinology

Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo Technology Platform in the American Journal of Rhinology & Allergy

We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients with Chronic Rhinosinusitis

Lyra Therapeutics, Inc.(NasdaqGM:LYRA) dropped from Russell 3000E Value Index

Lyra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for LYR-210 for the Treatment of Chronic Rhinosinusitis

Price target decreased to US$26.75

We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

Lyra Therapeutics, Inc., Annual General Meeting, May 26, 2021

How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Lyra Therapeutics, Inc. to Report Q4, 2020 Results on Mar 09, 2021

Lyra Therapeutics Announces Appointment of Robert Kern as Chief Medical Officer